Houston Biotech Oncolix Announces Reverse Merger, Goes Public

09:11 EDT 7 Aug 2017 | Xconomy

[Updated 8/7/17, 10:25 am. See below.] Houston—Oncolix, which is developing a treatment for ovarian cancer, announced Monday it has completed a reverse merger with Advanced Environmental Petroleum Producers (AEPP), making it a public company. The Houston-based Oncolix currently has ongoing a Phase I clinical trial in ovarian cancer patients for its prospective therapy, G129R (Prolanta). […]

Original Article: Houston Biotech Oncolix Announces Reverse Merger, Goes Public


More From BioPortfolio on "Houston Biotech Oncolix Announces Reverse Merger, Goes Public"

Quick Search

Relevant Topics

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...